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Cigarette smoking is a major risk factor for cardiovascular disease (CVD) and the leading avoidable cause of death worldwide. Exposure to
secondhand smoke (SHS) increases the risk of CVD among non-smokers. Smoking cessation benefits all smokers, regardless of age or
amount smoked. The excess risk of CVD is rapidly reversible, and stopping smoking after a myocardial infarction reduces an individual’s risk
of CVD mortality by 36% over 2 years. Smoking cessation is a key component of primary and secondary CVD prevention strategies, but
tobacco use often receives less attention from cardiologists than other risk factors, despite the availability of proven treatments that improve
smoking cessation rates. Both psychosocial counselling and pharmacotherapy are effective methods to help smokers quit, but they are most ef-
fective when used together. The first-line medications licensed to aid smoking cessation, nicotine replacement therapy, bupropion and vareni-
cline, are effective in and appropriate for patients with CVD. An evidence-based approach for physicians is to routinely ask all patients about
smoking status and SHS exposure, advise all smokers to quit and all patients to adopt smoke-free policies for their home and car, and offer all
smokers in the office or hospital brief counselling, smoking cessation pharmacotherapy, and referral to local programmes where psychosocial
support can be sustained in person or by telephone. Like other chronic diseases, tobacco use requires a long-term management strategy. It
deserves to be managed as intensively as other CVD risk factors.
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Introduction
Tobaccouse is the leading preventable cause of deathworldwide, re-
sponsible for .5 million deaths annually, or 12% of all deaths.1 Car-
diovascular disease (CVD) causes 29% of tobacco-attributable
deaths.2 Approximately one-half of regular smokers will die of a
tobacco-related disease, losing on average 10 years of life compared
with never smokers.3,4 The proportion of deaths due to tobacco is
larger in high-income countries, where it is 18% and exceeds the pro-
portionof deaths attributed to high blood pressure (17%)or to over-
weight and obesity (8.4%).5 Globally, the toll of tobacco-attributable
mortality is rising and the burden is shifting fromhigh-income to low-
and middle-income countries. By 2030, tobacco use is expected to
account for .8 million deaths annually.5
More than half of the decline in CVD mortality over the past half
century was attributed to reductions in major CVD risk factors
including tobacco use.6 During this time, the prevalence of cigarette
smoking decreased substantially in North America and Europe, but
the decline has slowed in the past decade.7,8 In 2011, 19% of US
adults (21.6% of men, 16.5% of women) smoked cigarettes.7
Smoking prevalence among European countries varies but is general-
ly higher than in the USA.2 A substantial proportion of individuals
continue to smoke even after they develop CVD. In Europe, the
smoking prevalenceof individualswhohaveexperienced acardiovas-
cular event was 20.3% in 1995, 21.2% in 1999–2000, and 18.2% in
2006–07.9
Reducing tobacco use is a central goal of primary and secondary
prevention strategies for CVD.6,10 In the practice of clinical cardi-
ology, however, tobacco use is often the neglected CVD risk
factor, receiving far less attention than hypertension, hyperlipid-
aemia, or diabetes. This is not consistent with delivering evidence-
based high-quality care. Effective smoking cessation treatments
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exist, and cardiologists have the responsibility to use these treat-
ments as actively as they treat other CVD risk factors. This review
will summarize the evidence base for treating tobacco users and
outline a strategy that can be implemented in clinical practice. The
review focuses on cigarettes because they are the most common
form of tobacco used worldwide and because the bulk of evidence
about treatment derives from studies in cigarette smokers. Informa-
tion about other forms of smoked and smokeless tobacco products,
including snus and electronic cigarettes, are available elsewhere.11,12
Cardiovascular risks of cigarette
smoking and exposure to
secondhand smoke
Tobacco use is a well-established risk factor for CVD incidence and
mortality.3,13 Smoking increases an individual’s risk of death from all
vascular diseases two- to three-fold3 (Figure 1). Worldwide, 10–
30% of all CVD deaths are attributable to tobacco.1,14 Among men
aged 30–44 years, however, 48% of cardiovascular deaths are attrib-
utable to tobacco use.1 Smokers’ excess risk of CVD increases with
numberof cigarettes smokeddaily, but existseven for smokersofone
to five cigarettes per day.14 Few data exist about occasional (non-
daily) smoking, but in one study men but not women who smoked
cigarettes occasionally had an increased risk of total and cardiovascu-
lar mortality.15
Cigarette smoking has been specifically identified as a cause of cor-
onary heart disease (CHD) [including myocardial infarction (MI) and
sudden death], cerebrovascular disease (stroke), peripheral artery
disease (PAD), and abdominal aortic aneurysm.16–18 Smokers risk
of heart failure is twice the risk of non-smokers, and smokers with
heart failure have a worse prognosis than non-smokers with heart
failure.19 Smoking can also induce andworsen serious cardiac arryth-
mias by many mechanisms.20
Among individuals with established CVD, smoking reduces the
success of treatments. Smokers who undergo percutaneous coron-
ary interventions (PCIs) orcoronaryarterybypass graft surgeryare at
increased risk of myocardial re-infarctions and death compared with
non-smokers.21,22 Current smoking is an independent predictor of
long-term stent thrombosis after PCIs.23 Cigarette smoking also
influences the efficacy of antiplatelet therapies. It is correlated with
aspirin resistance, probably due to its stimulating effect onplatelet ag-
gregation.24 Cigarette smoking (but not nicotine alone) induces the
cytochrome P450 1A2 (CYP1A2), which is involved in the metabol-
ism of clopidogrel. This results in greater inhibition of platelet aggre-
gation in smokers compared with non-smokers.25 This finding is
corroborated by a study suggesting that clopidogrel is effective in
smokers with CVD to preventing all-cause and cardiovascular mor-
tality but not in non-smokers or former smokers.26Newer antiplate-
let therapies (prasugrel, ticagrelor, and ticlopidine) donot seemtobe
influenced by smoking.
The cardiovascular risk of tobacco use is not limited to smokers.
Non-smokers who are regularly exposed to other people’s
tobacco smoke also have an increased risk of CVD. Exposure to
secondhand smoke (SHS) increases the risk of CHD morbidity and
mortality by 25–30% among non-smokers.27 Globally, CVD is re-
sponsible for .87% of the estimated 430 000 adult deaths caused
by SHS.28 The risk is rapidly reversible, as shown in multiple studies
documenting a rapid decline in hospital admissions for MI after the
adoption of smoking bans.29 In ameta-analysis of 11 studies assessing
the cardiovascular benefits of bans on smoking in public places, there
was anoverall 17%decreased riskof acuteMI after implementationof
smoking bans in public places.29 ACochrane review has also shown a
consistent reduction in hospital admissions for cardiac events after
smoking bans have been implemented.30
Figure 1 Cardiovascular mortality for current smokers compared to never smokers (hazard ratios were adjusted for age, educational level,
alcohol consumption, and body-mass index. Adapted from Jha et al.3). HR, hazard ratios; CI, confidence intervals.
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Pathophysiology of cardiovascular
disease risk
Cigarette smoking hasmultiple adverse effects on the cardiovascular
system that promote atherogenesis and trigger acute cardiovascular
events. Cigarette smoke induces CVD through endothelial injury,
formation of atheroma and a superimposed prothrombotic influ-
ence.31 The effects of cigarette smoking on CVD are mediated
through three principal constituents: nicotine, carbon monoxide
(CO), and oxidant gases. (Figure 2) Other authors have described
in details the biochemical mechanisms of nicotine on the cardiovas-
cular system,31,32 we will here summarize the main mechanisms.
Nicotine binds to nicotinic cholinergic receptors in the brain and
acts as a sympathomimetic agent.33 It stimulates the release of cate-
cholamines, leading to increases in heart rate, blood pressure, and
myocardial contractility that increase myocardial work and oxygen
demand.34 Nicotine also induces vasoconstriction through its
action on alpha-adrenergic receptors and by inducing endothelial
dysfunction.31,35 This results in a reduced coronary and cerebral
blood flow.
Carbon monoxide is produced by combustion and is found in cig-
arette smoke. It binds more avidly than oxygen to haemoglobin and
decreases oxygen supply to organs in the body. It results in relative
hypoxaemia that can precipitate ischaemic events. In addition, in
response to hypoxaemia, red blood cell mass increases and lead to
hyperviscosity, which contributes to hypercoagulation in smokers.32
Cigarette smoke contains high levels of oxidant gases such as
oxides of nitrogen and free radicals. These induce inflammation,
endothelial dysfunction, and oxidation of lipids, which are mediators
in the pathogenesis of CVD. They also contribute to platelet activa-
tion, thrombogenesis,36 and enhance coagulability through increase
in plasma fibrinogen.37 Other components of cigarette smoke, such
as metals and polycyclic aromatic hydrocarbons, also damage endo-
thelial cells and contribute to atherosclerosis.
The increase in risk of CVD associated with smoking is also
mediated thoughother cardiovascular risk factors such as an increase
in low-density lipoprotein-cholesterol and triglyceride, a decrease in
high-density lipoprotein cholesterol, an increased risk of type 2 dia-
betes, and possibly an increase in blood pressure.38–40
Health benefits of smoking
cessation: a rapid reduction in
cardiovascular disease risk
Smoking cessation benefits virtually all smokers, regardless of the
duration or intensity of their smoking, degreeof illness, or age at quit-
ting.13,41 Smoking cessation early in life is particularly beneficial.3
Figure 2 Pathophysiological effect of cigarette smoking and nicotine on cardiovascular disease. HR, heart rate; BP, blood pressure; NO, nitrogen
monoxide. Figure reprinted with permission from Salahuddin S, Prabhakaran D, Roy A. Pathophysiological mechanisms of tobacco-related CVD.
Global Heart. 2012;7(2):113–119.
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Stopping smoking before the age of 40 years reduces the risk of
tobacco-attributable death by 90%,3 but quitting at any age reduces
mortality rates.13
Quitting smoking reduces smokers’ risk of MI and stroke, and
smokers’ excess risk of CVD is rapidly reversible after smoking ces-
sation.42 Nearly, half of the excess CHD risk is eliminated within 2
years of quitting43(Figure 3). The risk of stroke is approximately the
same as a non-smoker 5 years after quitting smoking.44 Among
smokerswith PAD, cessation decreases the5-year riskof amputation
by 10 times and decreases mortality by 50%.45 Among smokers with
CHF, smoking cessation decreases mortality by 30% within 1 year
after cessation.19 Rapid improvements in endothelial function and
hypercoagulability among smokers who quit may underlie these epi-
demiological observations.46
Stopping smoking after acute coronary syndrome (ACS) or MI is
one of the most effective actions for secondary prevention of
CVD. A significant morbidity reduction has been observed within 6
months after an ACS among smokers who quit, compared with
thosewho do not.47 Smokers who quit after anMI have a 36% reduc-
tion in CVD mortality over 2 years compared with continuing
smokers.48
Stopping smoking also improves clinical outcomes after CABG
surgery or PCIs. Smokers who quit after CABG, compared with
those who continue to smoke, improve their survival and reduce
their risk of additional procedures.49 Stopping smoking after a PCI
decreases a smoker’s excess risk of death compared with individuals
who continue to smoke.21,50
Challenges to success in smoking
cessation
Surveys of US adults consistently report that70%of smokers want
to quit smoking andmore than half tried to do so in the past year, but
only 6%of thosewhoattempted toquit succeeded.51One reason for
the low success rate is that few smokers use any tobacco cessation
treatment when attempting to quit. Only one-third of US smokers
making a quit attempt seek assistance.52 Even in the UK, which has
anational systemof tobacco treatment andcoverage formedications,
only half of smokers who made a quit attempt in 2011 used a
cessation aid.53 Smoking cessation rates in the population could be
improved if more smokers used evidence-based treatment when
they tried to quit. The healthcare delivery system is a key channel
for accomplishing this goal. Physicians and other clinicians have a
unique opportunity to extend the reach of treatment to more
smokers and a responsibility to do so.
A major barrier to smoking cessation success is the addictive
nature of nicotine. Inhaling cigarette smoke rapidly delivers nicotine
to the brain, where it binds to nicotinic cholinergic receptors, leading
to a release of dopamine and other neurotransmitters that reinforce
smoking and the activities associated with smoking. Repeated smoke
exposure up-regulates nicotine receptors, produces tolerance to
higher doses of nicotine, and generates withdrawal symptoms
when nicotine levels fall.33 These symptoms include craving for cigar-
ettes, irritability, anger, restlessness, anxiety, depressed mood, diffi-
culty concentrating, insomnia, and increased hunger. They appear a
few hours after the last cigarette is smoked, peak within 48–72 h
and gradually wane to pre-cessation levels after 2–4weeks, although
cravings often continue.54
Smoking is also maintained by conditioned cues or stimuli whose
appearance triggers cigarette cravings. To stop smoking, therefore,
a smoker must manage pharmacological nicotinewithdrawal and ex-
tinguish the learned behavioural associations with smoking. This dual
challenge leads many individual quit attempts to fail. Most smokers
need several quit attempts before being successful for the long
term. Factors associated with a less success in quitting include a
high level of nicotine dependence, less education, comorbid psychi-
atric illness, other substance use, co-habitation with another
smoker, less social support for quitting, and low self-confidence in
the ability to quit. Individuals with these conditions can quit but
often require more intensive or prolonged treatment.
Smoking cessation treatment
Evidence from randomized controlled trials has clearly identified
psychosocial support (i.e. counselling) and pharmacotherapy as two
categories of effective smoking cessation treatment.41,55–59 Psycho-
social support enhances motivation to quit smoking and builds
coping skills to avoid relapse, while pharmacotherapy relieves nicotine
withdrawal symptoms. Combining them produces higher quit rates
than using either one alone.60While success increases with increasing
treatment intensity, even brief advice to quit by a physician or other
clinician is effective.41Hypnosis and acupuncturehavenot shown long-
term efficacy for smoking cessation in clinical trials.41
The traditional recommendation to smokers is to quit abruptly
after a short period of preparation.41 However, evidence suggests
that gradually reducing cigarette intake with the clear goal of future
quittingmayproduce comparable success.61 Far less evidence is avail-
able to guide smokers who are not ready to make a quit attempt, al-
though motivational interviewing counselling techniques appear to
be useful.62
The relapsing pattern of tobacco use among smokers who try to
quit has led to framing tobacco use as a chronic condition or
chronic disease.41 This has implications for treatment. Successful
treatment of other chronic diseases like diabetes, hypertension,
and CVD require a long-term management strategy, and smoking
requires the same approach.63
Figure 3 Benefits of quitting smoking on of the incidence of cor-
onary heart disease. RR, risk ratio;CHD, coronary heart disease;CI,
confidence interval; y, years. Figure adapted from Kawachi et al.43
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Smoking cessation counselling
Among smokers with CHD, psychosocial interventions for smoking
cessation increase 1-year smoking abstinence rates (OR: 1.66, 95%
CI: 1.25 to 2.22) according to a meta-analysis of 16 randomized con-
trolled trials.64 These interventions use cognitive-behavioural
therapy methods.
Psychosocial methods were initially designed for in-person deliv-
ery to individuals or groups, but to reach more smokers, the techni-
ques have been adapted for delivery by telephone (voice and text
messaging), on the web, and via social media.65 Strong evidence sup-
ports the efficacy of delivering smoking cessation counselling as a
seriesof proactive (i.e. counsellor-initiated) telephonecalls; so-called
‘quitlines’ exist in many countries.66 Text messaging is also effective
for smoking cessation.67 There is as yet less evidence to demonstrate
the efficacy of web-based programmes and no data on smart phone
applications.
Pharmacotherapy
Strong evidence supports the efficacy of three medications to help
smokers quit. They are nicotine replacement products, bupropion,
and varenicline. They are ranked as equivalent first-line treatment
choices in US clinical practice guidelines and further described
below41 (Table 1).
Of these three medications, bupropion is the only one to have po-
tential interactions with major drug classes used in cardiology. Bupro-
pion is mainly metabolized by the cytochrome P450 2B6 and
concomitant use of drugs acting on this isoenzyme (mainly clopidogrel
in cardiology) can increase the blood levels and effects of bupropion.
Nortriptyline, a tricyclic antidepressant, and clonidine, an antihy-
pertensive agent, have also demonstrated efficacy for smoking cessa-
tion but their evidence base is smaller and they are ranked as
second-line treatments in theUS guidelines.41Cytisine, a partial nico-
tine receptor agonist with chemical similarities to varenicline, is a
low-cost drug marketed in some Eastern European countries as
Tabexw. It showed efficacy in a randomized controlled trial but is
not currently licensed for smoking cessation in western European
Union countries or North America.68 Selective serotonin reuptake
inhibitor antidepressants and anxiolytic agents have not demon-
strated efficacy for smoking cessation in randomized controlled
trials.41
Nicotine replacement therapy
Efficacy
Nicotine replacement therapy (NRT) reduces nicotine withdrawal
symptoms to help a smoker to stop the behaviour of smoking. In a
meta-analysis of over 100 trials, NRT increased smoking abstinence
ratesoverplacebo (RR: 1.60, 95%CI: 1.53–1.68).57Nicotine replace-
ment therapy products are roughly equal in efficacy but have two
distinct patterns of nicotine delivery. The skin patch delivers nicotine
for 16–24 h with a single application but with a slow onset of action
(2–3 h). In contrast, nicotine in the gum, lozenge, inhaler, mouth
spray, or nasal spray has a more rapid onset (5–30 min) but a
shorter duration of action. These products must be reused through-
out a day to maintain stable nicotine blood levels. As randomized
controlled trials demonstrate, the most effective way to use NRT is
to combine the nicotine patch with a short-acting orally or nasally
absorbed product.69 The short-acting product is used as needed to
relieve cravings that arise in the presence of the NRT patch.
Surprisingly, clinical trials of the efficacy of NRT in patients with
CVD had mixed results, in part because few trials have been con-
ducted.70–72 The largest trial did not find a sustained efficacy over
time of NRT in outpatients with stable CVD.70 Two other studies
found that NRT was superior compared with placebo but both had
very short follow-up (2 and 5weeks).71,72Despite its lackof clear evi-
dence of efficacy in the setting of CVD, NRT is considered to be ef-
fective in CVD patients based on the substantial evidence base for
smokers in general.
Safety
Theoretically, nicotine’s sympathomimetic effect could increase
myocardial workload and adversely affect patients with CVD, espe-
cially those with unstable CHD syndromes. However, the nicotine
transdermal patch is not associated with an increased cardiovascular
risk in patients with stableCVD.70,72,73 A study that did stress tests in
smokers while actively smoking and while using nicotine patches
found less exercise-induced myocardial ischaemia in the nicotine
patch condition than in the smoking condition.74
Both the US Clinical Practice Guidelines and the UKMedicine and
Healthcare Products Regulatory Agency endorse the use of NRT in
peoplewith stableCVD.41,75 Little direct evidence is available regard-
ing the safety of NRT in patients with severe or unstable angina, ACS,
or recent stroke. A case for NRT’s relative safety in acute CVD or
recent MI can be made from indirect evidence. First, nicotine’s
adverse haemodynamic effects, which increase myocardial work,
depend on its rapidity of absorption, which is slower for the patch
than for smoking.75 Second, hypercoagulability and CO play a more
important role than the haemodynamic effects mediated by nicotine
in precipitating acute coronary events.75 Nicotine patches lack the
thrombogenic effect of cigarette smoking and do not expose the
smoker to CO. Therefore, it is reasonable to consider using NRT
to treat nicotine withdrawal symptoms and promote smoking cessa-
tion once an ACS event is haemodynamically stabilized if non-
pharmacological interventions are not sufficient.75
Varenicline
Efficacy
Varenicline is a selective partial agonist of the alpha4-beta2 nicotine
receptor. It has a dual mechanism of action. It relieves nicotine with-
drawal symptoms by stimulating nicotinic receptors and blocks the
reinforcement of smoking by preventing nicotine from binding to
the receptors. Compared with placebo, varenicline more than
doubles quit rates over 6–12 months, according to the most
recent meta-analysis (RR: 2.32, 95% CI: 2.06–2.61).58 Varenicline
was superior to bupropion in two head-to-head trials58,76 and was
better (with borderline statistical significance) than NRTmonother-
apy in one open-label randomized controlled trial.77 No study has
directly compared varenicline with combination NRT.
Theefficacyof varenicline inpatientswith stableCVDwastested in
one double-blind randomized controlled trial of over 700 smokers.78
In that trial, varenicline increased continuous tobacco abstinence at 1
year compared with placebo (OR: 3.14, 95% CI: 1.93–5.11).
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Table 1 Medications that are licensed in USA or Europe as aids for smoking cessation
Medication Efficacy in all
patients (RR
with 95% CI)a
Efficacy in CVD
patients
Common adverse
effects
CVD safety Advantages Disadvantages and warnings Dose Duration
(months)
Nicotine replacement
therapy
1.60 (1.53–1.68) Few randomized trials
with mixed results in
outpatients with
CVD
Vary by NRT product Safe in stable CVD. Weigh
benefit vs. risk if recent
MI (,2 week), unstable
angina, ventricular
arrhythmia
Often availablewithout
prescription
Vary by NRT product Varies by product 2–6
Skin patch: 21 mg/
14 mg/7 mg
(for 24 h); 25 mg/
15 mg/10 mg
(for 16 h)
1.66 (1.53–1.81) Skin irritation, insomnia Easiest to use, provides
steady nicotine level
Nicotine released slowly, does not
allow smoker to respond to
cravings
Apply 1patchdaily: 21 mg/25 mg
for ≥ 10 cig/day, 14 mg/
15 mg for ,10 cig/day,
taper to lower dose after 4–
6 weeks
≥2–3
Gum: 2 mg, 4 mg 1.43 (1.33–1.53) Mouth irritation, jaw
soreness, heartburn,
hiccups, nausea
User controls nicotine
dose
Oral substitute for
cigarettes
Proper chewing technique
required, difficult to use if
dental problems, no food or
drink for 30 min before use and
during use
1 gum every hour
4 mg for ≥ 25 cig/day
2 mg for , 25 cig/day
Max 24 gums/day
≥3
Lozenge: 1 mg/2 mg/
4 mg
Microtab
sublingual: 2 mg
2.0 (1.63–2.45) Hiccups, heartburn User controls nicotine
dose
No food or drink for 30 min
before use and during use
1 piece every 1–2 h 3–6
Oral inhaler: 10 mg per
cartridge
1.90 (1.36–2.67) Mouth and throat
irritation, cough
User controls nicotine
dose
Oral substitute for
cigarettes
Device visible when being used Inhale as needed
Max 16 cartridges/day
3–6
Nasal spray: 10 mg/ml 2.02 (1.49–3.73) Nasal irritation, sneezing,
cough, teary eyes
User controls nicotine
dose
Most rapid delivery
of nicotine
Local irritation to nasal mucosa
(not on sale in all European
countries)
Applyonce to eachnostril 1–2/h
Max 40 applications/day
3–6
Mouth spray: 1 mg per
spray dose
2.48 (1.24–4.94) Mouth and throat
irritation, hiccups,
heartburn
User controls nicotine
dose
Oral substitute for
cigarettes
Local irritation (only on sale in the
UK)
1–2 sprays, up to 4 sprays per
hour. Max 64 sprays per 24 h
3–6
Bupropion SR: 150 mg 1.69 (1.53–1.85) Efficacy in randomized
trial of outpatients
with stableCVD(OR:
2.78, 95% CI: 1.70–
4.63)
Insomnia, headache,
dry mouth
Safe Blunts post cessation
weight gain while
being used
Increases seizure risk,
FDA boxed warning about
psychiatric effectsb
150 mg/day for 3 day then
150 mg 2×/day
Start 1 week before quit date
3–6
Varenicline: 0.5 mg/
1 mg
2.27 (2.02–2.55) Efficacy in randomized
trial of outpatients
with stableCVD(OR:
3.14, 95% CI: 1.93–
5.11)
Nausea, insomnia,
headache
FDA advisory about
potential CVD risks
but absolute risk very
low (,1%)c
Dual action: relieves
nicotine withdrawal
and blocks reward
from smoking
FDA boxed warning about
psychiatric effectsd
Reduce dose in moderate to
severe renal insufficiency
0.5 mg/day for 3 days, then
0.5 mg 2×/day for 4 days,
then 1 mg 2×/day
Start 1 week before quit date
3–6
aData from Cochrane reviews.
bhttp://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm169988.htm
chttp://www.fda.gov/Drugs/DrugSafety/ucm330367.htm
dhttp://www.fda.gov/Drugs/DrugSafety/ucm276737.htm#
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Safety
The most common side effects of varenicline are nausea, insomnia,
and vivid or abnormal dreams. Varenicline was expected to have
no cardiovascular risk because it does not bind to the nicotine recep-
tor subtypes thatmediatenicotine’s haemodynamic effects. The large
randomized trial of varenicline in patients with stable CVD observed
no adverse effects on CVD events or mortality over one year.78
Three meta-analyses that pooled safety data from multiple vareni-
cline clinical trials have disagreed among themselves. One
meta-analysis found an increased risk of serious adverse cardiovascu-
lar events associated with varenicline (Peto OR: 1.72, 95% CI: 1.09–
2.71).79 This was not found in a secondmeta-analysis (OR: 1.41, 95%
CI: 0.82–2.42)80 or a third one mandated by the US FDA and
reported in December 2012 (adjusted hazard ratio 1.95, 95% CI:
0.79–4.82).81 In all studies, the absolute riskof serious cardiovascular
events was very low (1% or less at 6–12 months). Even if present, a
small risk of varenicline would likely be counterbalanced by its ability
to enhance smoking cessation, which has rapid and substantial bene-
fits on cardiovascular health.
A potential association of varenicline with behavioural changes
such as hostility, agitation, depressed mood, and suicidal thoughts
or actions has appeared in case reports. Interpreting them is challen-
ging because nicotine withdrawal alone can produce these symp-
toms. A meta-analysis of randomized control trials of varenicline
detected no increase in psychiatric illness in patients taking the
drug.82 However, people with depression or mental illnesses were
not included in these studies. Two studies of electronic health
records detected no associationof vareniclinewith psychiatric symp-
toms83 or neuropsychiatric hospitalizations.84 A large FDA-
mandated randomized controlled trial is ongoing.85 In themeantime,
smokers started on varenicline deserve close follow-up to monitor
for these symptoms.
Bupropion
Efficacy
Bupropion, an atypical antidepressant that increases dopamine and
norepinephrine levels in the central nervous system, increased
smoking cessation rates by 69% compared with placebo (RR: 1.69,
95% CI: 1.53–1.85) in a recent meta-analysis of randomized
trials.58 In a large trial of outpatient smokerswith stable CVD, bupro-
pion doubled the continuous abstinence rate compared with
placebo.86 However, long-term efficacy for bupropion was not
observed in three trials in which bupropion was started in hospita-
lized smokers with acute CVD events and continued after dis-
charge.87–89 These trials had relatively high smoking cessation rates
in the control groups (ranging from 21 to 37%), perhaps reflecting
the greater efficacy of counselling (the control condition) among
smokers hospitalized with acute CVD.
Safety
The main side effects of bupropion are insomnia, headache, and
dry mouth. It is contra-indicated in patients with or at risk for
seizure. Studies of bupropion in patients with CVD have not shown
an increase in CVD-specific adverse events compared with
placebo.86–89
Incorporating smoking cessation
treatment into clinical practice
Physicians can influence their patients’ smoking behaviour, primarily
by prompting smokers to make a quit attempt. Physicians who rou-
tinely deliver brief advice to quit to all smokers increase smokers’
odds of quitting by 34%.56 Going beyond advice to provide a short
counselling intervention during an office visit is more effective.
Cardiologistshavea specialopportunity topromotecessation. Fora
smoker, the diagnosis of CHDmakes the health risks of smoking sud-
denly personally salient. Informing smokers that they have the ability to
rapidly reduce the risk of future CVD events by quitting smoking is in-
formation with the potential to be highly motivating. Additionally, the
cardiovascular risks of SHS exposure are not well known. Cardiolo-
gists should provide this new information by asking all patients if
anyone at home smokes and advise every patient, regardless of
smoking status, to adopt a smoke-free policy for the home and car.
Hospitalization is another opportunity for cardiologists to encour-
age smokingcessation. If thehospital is smoke-free, smokersmust tem-
porarily refrain from tobacco use. They can be encouraged to remain
tobacco abstinent after discharge and start smoking cessation counsel-
ling and pharmacotherapy in the hospital. In a meta-analysis of rando-
mized controlled trials of smokers hospitalized for a CVD diagnosis, a
smoking cessation intervention started in the hospital and sustained,
usually by telephone, for at least 1 month after discharge, increased
smoking cessation rates by 42% (RR: 1.42, 95% CI: 1.29–1.56) 6–12
months after discharge.55 Starting NRT in hospital increased quit
rates over counselling alone.55 In one trial of smokers hospitalized
withMI, an intensive interventionof counselling andpharmacotherapy,
compared with usual care, not only increased smoking cessation but
also reduced all-cause mortality and hospital readmissions.90
Guidelines for CVD prevention from the American Heart Associ-
ation (2011)10 and European Society of Cardiology (2012)6 clearly
identify smoking cessation as a key component of CVD prevention.
Both theUS and EuropeanGuidelines onCVDprevention clearly rec-
ommend against use of tobacco and exposure to SHS. They strongly
advise that all smokers should be given advice to quit and be offered
assistance that includes counselling and pharmacotherapy. The 2012
European Guidelines on CVD prevention in clinical practice include
10 ‘strategic steps’ to guide physicians who seek to help their patients
alter any behavioural cardiovascular risk factor.6 They provide a prac-
tical framework for addressing tobacco use in office practice.
The 2008 US Public Health Service guideline translated evidence
from clinical trials into a five-step model for addressing tobacco use
in office practice (5 As) (Figure 4).41 This consists of (i) systematically
asking and documenting every patient’s smoking status at every visit,
(ii) advising all tobaccousers toquit, emphasizing thepersonal benefits
of cessation rather than the harms of continuing to smoke, (iii) asses-
sing their intentions to quit and degree of addiction, (iv) assisting
themwith quitting by prescribingmedication and referring to counsel-
ling resources in the community or health care system, and (v) arran-
ginga follow-upvisit. Linkingsmokers totelephonequitlines is standard
care in countries where these are available. Referring to websites is
another alternative if in-person counselling is not readily available.
An alternative, briefer three-step model for cardiac patients con-
sists of the following: (i) Ask all patients about tobacco use and
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SHS exposure; (ii) advise all smokers to quit and all non-smokers to
avoid SHS; and (iii) refer to community resources such as quitlines or
websites. Prescribing pharmacotherapy to patients planning to quit is
implicit but not explicit in this model (Figure 4).
Conclusions and
recommendations: the
cardiologist’s role
Cigarette smoking is universally recognized as a major risk factor for
CVD. Smoking cessation reliably and rapidly reduces the excess risk,
even among individuals who have already developed clinical CVD. A
large body of evidence has demonstrated the efficacy of pharmaco-
therapy and psychosocial support for assisting smokers to quit and
stay quit. Tobacco treatment is among the most cost-effective treat-
ments forCVD91 and is endorsedbyprofessionalorganizationsof car-
diologists inNorthAmericaandEurope.6,10Clearly, treatingsmoking is
the standardofcare for theprimaryandsecondarypreventionofCVD.
Despite this unequivocal evidence, tobacco is often the forgotten
cardiac risk factor, receiving less of a cardiologist’s attention than is
given to treating hypertension, hyperlipidaemia, or diabetes.92 This
should change. Cardiologists must recognize that tobacco use has
the characteristics of a chronic condition or chronic disease and
deserves to be treated like one. Treating a smoker requires taking a
long-term management approach that is no different from other
chronic diseases. Routinely identifying smoking status, advising cessa-
tion, and referring to resources to assist smokers in making a quit
attempt should be standard practice and quality measures.
Cardiologists shouldalsocommunicate toall patients thenewerand
less well-known information about SHS exposure as a risk factor for
CVD. Cardiologists should routinely ask about SHS exposure, advise
all patients to adopt smoke-free policies for their homes and vehicles
and recommend avoiding SHS exposure at work and in public places.
Cardiologists can also contribute as rolemodels and advocates. As
role models, cardiologists should not use tobacco products them-
selves. Cardiologists can advocatewith their hospitals and healthcare
systems to adopt smoke-free policies and make tobacco treatments
Figure 4 Alternative strategies for addressing tobacco use and secondhand smoke exposure in clinical practice. SHS, second-hand smoke; fup,
follow-up. Note: adapted from 5As41, ESC guidelines6 and ‘Cardiology Rx for Change’94 with modifications by the authors. 1Quitlines: US:
800-QUIT-NOW. Map to locate quitlines elsewhere in the world: http://c.ymcdn.com/sites/naquitline.site-ym.com/resource/resmgr/
GQN_Map/worldmap.swf.2 Examples of web-based programmes: becomeanex.com, quintet.com.3 Examples of in-person programmes:
NHS Stop Smoking Service (www.nhs.uk).
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available and affordable. Cardiologists in academic settings can advo-
catewithmedical schools and training programmes to teach tobacco
treatment methods to the next generation of physicians. Finally, in
their communities, cardiologists can support the adoption of com-
prehensive tobacco control public policies that are proved to
reduce tobacco use.93
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